Will increasing the dose of osimertinib be more effective?

Osimertinib is a targeted therapy drug for non-small cell lung cancer (NSCLC), and its efficacy and safety have been widely recognized in clinical practice. However, the question of whether increasing the dose of osimertinib will make the effect better is not a simple question of right or wrong, but needs to be comprehensively judged based on the patient's specific situation, the pharmacological effects of the drug, and the results of clinical studies.

From the pharmacological effect of the drug, osimertinib prevents the growth and spread of tumors by inhibiting specific proteins in tumor cells. Increasing the drug dose may enhance its inhibitory effect on tumor cells, but may also increase the risk of adverse reactions. Therefore, efficacy and safety need to be weighed when adjusting dosage.

The results of clinical studies also provide us with certain references. According to publicly released information, some studies have shown that in certain circumstances (such as meningeal metastasis or EGFR 20ins mutations), increasing the dose of osimertinib may bring about certain therapeutic effects. For example, in a study of patients with meningeal metastases, 160 mg of osimertinib daily significantly prolonged progression-free survival and overall survival compared with the standard dose of 80 mg. However, these findings do not apply to all conditions and are not meant to apply to all patients.

Individual patient differences and tolerances also need to be considered. Each patient's response to and tolerance of medications is different, so the dose of medication cannot be increased arbitrarily. Before deciding whether to increase the dose of osimertinib, a comprehensive evaluation should be conducted, including the patient's specific condition, severity of disease, and possible efficacy and safety.